2. Signaling Pathways
  3. Metabolic Enzyme/Protease
    Neuronal Signaling
  4. Dihydroceramide Desaturase 1 (DES1)

Dihydroceramide Desaturase 1 (DES1)

Dihydroceramide Desaturase 1; DES1; DEGS1

Dihydroceramide Desaturase 1 (DES1) is mainly located in the endoplasmic reticulum, and catalyzes the conversion of dihydroceramide to ceramide through introduction of a 4,5-trans double bond. Dihydroceramide Desaturase 1 promotes the ceramide synthesis and sphingolipid metabolism, induces the cell apoptosis and autophagy, and regulates endoplasmic reticulum stress. Dihydroceramide Desaturase 1 dysfunction could cause ceramide abnormal accumulation, thereby affecting insulin signaling, leading to insulin resistance and fatty liver. Dihydroceramide Desaturase 1 also causes cancer or some neurological disorders[1].

Dihydroceramide Desaturase 1 (DES1) Related Products (4):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-135818
    XM462
    		Inhibitor 99.80%
    XM462 is a dihydroceramide desaturase inhibitor. XM462 produced a mixed-type inhibition (Ki=2 μM) in vitro. XM462 has dihydroceramide desaturase inhibition both in vitro and in cultured cells with IC50 values of 8.2 and 0.78 μM, respectively. XM462 can be used for the research of tumor.
    XM462
  • HY-W673679
    (1R,2S)-Deoxy-PR280
    (1R,2S)-Deoxy-PR280 is a competitive inhibitor of dihydroceramide desaturase, with a Ki of 6 µM.
    (1R,2S)-Deoxy-PR280
  • HY-163472
    PR280
    		Inhibitor 98.69%
    PR280 is a dihydroceramide desaturase 1 (Des1) inhibitor with an IC50 of 700 nM. PR280 is used for the research of metabolic diseases, cancers, and neurodegenerative diseases.
    PR280
  • HY-183723
    GAA-4OH
    		Inhibitor
    GAA-4OH is a potent and irreversible dihydroceramide desaturase-1 (DES1) inhibitor with an IC50 of 0.6 μM and a Ki of 139.5 nM. GAA-4OH undergoes oxidation to form a reactive iminoquinone that covalently blocks DES1’s catalytic cavity, causing permanent enzyme inactivation. GAA-4OH modulates sphingolipid balance by reducing ceramide-to-dihydroceramide ratios in liver tissue. GAA-4OH improves liver steatosis, inflammation, fibrosis, and reduces pro-inflammatory and pro-fibrogenic gene expression. GAA-4OH can be used for the research of metabolic dysfunction-associated steatotic liver disease (MASLD).
    GAA-4OH